Takeda Pharmaceutical Co. $TAK Stock Position Lifted by Capital Research Global Investors

Capital Research Global Investors increased its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 0.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,486,772 shares of the company’s stock after buying an additional 82,643 shares during the quarter. Capital Research Global Investors owned about 0.42% of Takeda Pharmaceutical worth $210,259,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. UBS Group AG lifted its holdings in shares of Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after buying an additional 1,869,323 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after buying an additional 692,404 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Takeda Pharmaceutical by 132.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock valued at $41,413,000 after buying an additional 1,610,088 shares during the period. Qube Research & Technologies Ltd lifted its holdings in shares of Takeda Pharmaceutical by 407.9% in the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after buying an additional 1,426,184 shares during the period. Finally, Managed Asset Portfolios LLC lifted its holdings in shares of Takeda Pharmaceutical by 0.6% in the fourth quarter. Managed Asset Portfolios LLC now owns 1,495,746 shares of the company’s stock valued at $23,319,000 after buying an additional 9,338 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Wall Street Analyst Weigh In

TAK has been the subject of several research analyst reports. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Wall Street Zen lowered Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Takeda Pharmaceutical in a report on Wednesday, April 29th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Trading Up 1.1%

Shares of NYSE TAK opened at $15.78 on Tuesday. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a market cap of $50.20 billion, a price-to-earnings ratio of 40.45 and a beta of -0.07. The company has a quick ratio of 0.70, a current ratio of 1.27 and a debt-to-equity ratio of 0.56. The business has a fifty day simple moving average of $16.92 and a 200-day simple moving average of $16.67.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 11.07% and a net margin of 4.31%.The business had revenue of $6.90 billion during the quarter. Sell-side analysts predict that Takeda Pharmaceutical Co. will post 1.56 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.